Navigation Links
Frost & Sullivan's Biopharmaceuticals Market Briefing to Address the Use of Embryonic Stem Cells
Date:3/4/2009

MOUNTAIN VIEW, Calif., March 4 /PRNewswire/ -- The Healthcare practice at Frost & Sullivan is pleased to announce its 2009 Quarterly Analyst Briefing Presentation on the North American biopharmaceuticals market to be held on Thursday, March 5, 2009 at 10:00 a.m. PST.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

The biopharmaceutical industry has witnessed healthy growth and is experiencing several notable trends, such as the increased use of contract manufacturing organizations and the targeting of biotechnology companies for mergers and acquisitions by pharmaceutical companies or other biotechnology companies. In addition, this industry faces issues that are immersed in heated debate, such as the approval pathway of biosimilars.

This briefing will benefit strategic planners, business development managers, research professionals, marketing managers, and those who are considering entering this dynamic market. Highlights of the briefing include an analysis of overall market trends, general market sizing, and a look at selected issues.

"One of the hot topics in the biopharmaceutical market is the ethical debate surrounding the research and use of embryonic stem cells," notes Frost & Sullivan Research Analyst Katheryn Symank. "This issue is immersed in both political and ethical controversy. Some argue that the use of human embryonic stem cells is unethical while others support their use because of the potential medical good to the population."

To participate, please email Stephanie Ochoa, Corporate Communications, at stephanie.ochoa@frost.com with the following information: your full name, title, company name, company telephone number, company email address, city, state and country. Upon receipt of the above information, a registration link will be emailed to you. You may also register to receive a recorded version of the briefing at anytime by submitting the aforementioned contact details.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

    Contact:

    Stephanie Ochoa
    Corporate Communications - North America
    P: 210.247.2421
    F: 210.348.1003
    E: stephanie.ochoa@frost.com
   http://www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Perceptive Informatics Receives Frost & Sullivan Product Line Strategy Award
2. Pioneer(R) Surgical Technology, Inc. Wins Frost & Sullivans 2009 North American Orthopaedic Tissue Engineering Technology Innovation Award
3. Frost & Sullivan Names Naviscan a Leader in the Future of Molecular Breast Imaging
4. Frost & Sullivan Forecasts Early Rebound: Strong Growth Ahead for Global Economy
5. Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma
6. Frost & Sullivan Recognizes ESBATechs Innovation in Developing Antibody Fragments for Biologic Therapeutics
7. Ganeden Biotech Receives Frost & Sullivan Probiotics Product Innovation Award
8. Frost & Sullivan Commends Honeywell Enraf for Cutting-Edge Products and Post-Sales Support
9. Frost & Sullivan Recognizes Martek Biosciences for Unique and Customer-Focused Strategies With Customer Value Enhancement Award
10. Frost & Sullivan Awards Baxters BioPharma Solutions Business the 2008 North American Customer Service Leadership of the Year Award
11. Frost & Sullivan Presents CorMatrix Cardiovascular Inc. with 2008 Healthcare Innovation Award for the Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... 2017 , ... NetDimensions has been ranked as a Leader ... Corporate Learning, 2017. , Aragon Research defines Leaders as organizations who possess comprehensive ... those strategies. NetDimensionsā€™ ranking as a Leader due to its strengths in: , ...
(Date:5/23/2017)... Diego, CA (PRWEB) , ... May 23, 2017 , ... ... matrix of polymeric molecules, can cause diverse pathologies ranging from food poisoning and catheter ... impact of biofilms is in the tens of billions of dollars per year, there ...
(Date:5/22/2017)... ... 22, 2017 , ... Cancer diagnostics and pathology workflow solution ... the Association for Pathology Informatics Annual Summit at the Wyndham Grand ... Cancer Diagnostic Cockpit and Consultation Portal, Inspirata will present research it led to ...
(Date:5/18/2017)... ... May 18, 2017 , ... Dr. Ralph Mobbs ... the Prince Of Wales Private Hospital. The procedure was performed on a 46-year-old ... failed conservative treatments prior to undergoing surgery. , The AxioMed viscoelastic disc is ...
Breaking Biology Technology:
(Date:4/24/2017)... WASHINGTON , April 24, 2017 ... counsel and partner with  Identity Strategy Partners, LLP ... "With or without President Trump,s March 6, ... Foreign Terrorist Entry , refugee vetting can be instilled ... refugee resettlement. (Right now, all refugee applications are ...
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
Breaking Biology News(10 mins):